Praveen R. Arany BDS, MDS, MMSc, PhDAssistant Professor, Oral Biology & Biomedical Engineering, School of Dental Medicine, Engineering & Applied Sciences, University at Buffalo, Buffalo, New York; President, World Association for Photobiomodulation Therapy
Dr. Arany is trained as a dentist and an oral pathologist. He completed a joint PhD-Residency program at Harvard University as a Harvard Presidential Scholar. He has two certificates in clinical translational research from Harvard Medical School and the National Institute of Health. He pursued postdoctoral fellowships at the Indian Institute of Sciences, Bangalore, National Cancer Institute, Bethesda, and Harvard School of Engineering and Applied Sciences & Wyss Institute, Cambridge. Following his training, he served as an Assistant Clinical Investigator at the National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, from 2012 to 2015. Since 2015, he is a tenure-track Assistant Professor, Oral Biology, School of Dental Medicine, University at Buffalo, New York. He also has several adjunct positions in various institutes, including the National Institute of Aging, N.I.H., Baltimore, Biomedical Engineering, University at Buffalo, Nursing, Shepherd's University, and Physical Therapy, Manipal University.
He has over 80 scientific publications and is a recipient of numerous awards, such as the NCI Director's Young Investigator Award, Wound Healing Society's Young Investigator Award, Eugene Seidner scholar, and Horrace Furomoto Young Investigator award. He has been invited to speak in various national and international forums, reviews for over 50 scientific journals, serves 9 journal editorial boards, serves as an associate/academic editor in 4 journals, and reviews grants for national and international funding agencies.
He has held several leadership positions and continued to serve in various positions in the Wound Healing Society (W.H.S.), American Association for Dental Research (A.A.D.R), Academy of Laser Dentistry (A.L.D.), American Society of Lasers in Medicine (A.S.L.M.S), American Dental Education Association (A.D.E.A). He is the current President, World Association for Photobiomodulation Therapy (W.A.L.T), immediate past-president, North American Association for Photobiomodulation Therapy (N.A.A.L.T), Co-Chair of the International Society of Optics and Photonics (S.P.I.E) conference on Mechanisms of Photobiomodulation therapy and technical group member, Optical Society of America (O.S.A) Technical group on Photobiomodulation and Co-Director, Center for Excellence in Photobiomodulation in Nursing, West Virginia.
His work has over 5000 citations and has an h-index of 28, and i-10 index of 54 (source: Google scholar), and iCITE index of 180 (source: N.I.H.). His work has been featured in many mainstream media highlights in over 70 countries, including Fox News, CNN, M.S.N.B.C., Washington Post, B.B.C., Reuters, and M.I.T. technical review, among many others. His research is routinely featured in both print and public media.
Besides his academic interests in clinical translational research, Dr. Arany has co-founded two biotechnology companies to translate his lab research into real-world clinical solutions actively. He actively consults for several companies, academic and regulatory institutions. In the past decade, his research has been supported by about $5 million USD.
The overall scientific focus of the Arany lab is to identify key biological regulatory components that can be used in clinical studies to control biological outcomes. His research is predominantly focused on the molecular mechanisms and clinical translation of low dose light treatments, termed Photobiomodulation Therapy, to alleviate pain or inflammation and promote tissue healing and regeneration. Work from his group has unraveled several molecular pathways that are enabling the safe and effective clinical translation of this innovative treatment. His other areas of interest include smart (sense and respond, controlled release) biomaterial systems, the dichotomy of wounds and tumors, and TGF-β signaling.